1. Home
  2. ZBAI vs NXTC Comparison

ZBAI vs NXTC Comparison

Compare ZBAI & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZBAI
  • NXTC
  • Stock Information
  • Founded
  • ZBAI 2015
  • NXTC 2015
  • Country
  • ZBAI United States
  • NXTC United States
  • Employees
  • ZBAI N/A
  • NXTC N/A
  • Industry
  • ZBAI Professional Services
  • NXTC Biotechnology: Pharmaceutical Preparations
  • Sector
  • ZBAI Consumer Discretionary
  • NXTC Health Care
  • Exchange
  • ZBAI Nasdaq
  • NXTC Nasdaq
  • Market Cap
  • ZBAI 17.3M
  • NXTC 13.9M
  • IPO Year
  • ZBAI N/A
  • NXTC 2019
  • Fundamental
  • Price
  • ZBAI $0.49
  • NXTC $0.50
  • Analyst Decision
  • ZBAI
  • NXTC Strong Buy
  • Analyst Count
  • ZBAI 0
  • NXTC 2
  • Target Price
  • ZBAI N/A
  • NXTC $3.50
  • AVG Volume (30 Days)
  • ZBAI 962.4K
  • NXTC 147.5K
  • Earning Date
  • ZBAI 03-13-2025
  • NXTC 07-31-2025
  • Dividend Yield
  • ZBAI N/A
  • NXTC N/A
  • EPS Growth
  • ZBAI N/A
  • NXTC N/A
  • EPS
  • ZBAI N/A
  • NXTC N/A
  • Revenue
  • ZBAI $670,000.00
  • NXTC N/A
  • Revenue This Year
  • ZBAI N/A
  • NXTC N/A
  • Revenue Next Year
  • ZBAI N/A
  • NXTC N/A
  • P/E Ratio
  • ZBAI N/A
  • NXTC N/A
  • Revenue Growth
  • ZBAI 67.50
  • NXTC N/A
  • 52 Week Low
  • ZBAI $0.47
  • NXTC $0.22
  • 52 Week High
  • ZBAI $2.50
  • NXTC $1.82
  • Technical
  • Relative Strength Index (RSI)
  • ZBAI N/A
  • NXTC 55.61
  • Support Level
  • ZBAI N/A
  • NXTC $0.47
  • Resistance Level
  • ZBAI N/A
  • NXTC $0.52
  • Average True Range (ATR)
  • ZBAI 0.00
  • NXTC 0.04
  • MACD
  • ZBAI 0.00
  • NXTC 0.00
  • Stochastic Oscillator
  • ZBAI 0.00
  • NXTC 61.67

About ZBAI ATIF Holdings Limited Ordinary Shares

ATIF Holdings Ltd is a consulting company. It provides financial and advisory services to small and medium-sized enterprises and also to individual customers and families. The firm also offers Pre-IPO's, and Post-IPO's services. It operates in one operating segment which is the consulting service business. It generates the majority of its revenue from the USA.

About NXTC NextCure Inc.

NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

Share on Social Networks: